💊 Etibo 250 mg Tablet | Lapatinib | Targeted Oncology Therapy | Export Supplier
Etibo 250 mg Tablet contains Lapatinib, a tyrosine kinase inhibitor used in the treatment of HER2-positive breast cancer. It works by blocking growth signals in cancer cells, helping to slow disease progression under medical supervision.
🔹 Product Category
Oncology Medicine (Targeted Therapy)
🔹 Composition
Lapatinib 250 mg
🔹 Indications
✔ HER2-positive Breast Cancer
✔ Advanced / Metastatic Breast Cancer
✔ Used in combination therapy (as prescribed)
🔹 Key Benefits
✔ Targeted anti-cancer mechanism
✔ Helps inhibit tumor growth pathways
✔ Oral administration for convenience
✔ Widely used in oncology protocols
🔹 Dosage & Administration
✔ Oral tablet
✔ Strictly as prescribed by oncologist
✔ Often used in combination regimens
🔹 Regulatory & Safety Notice
✔ Prescription-only medicine
✔ Requires monitoring during treatment
✔ Export compliance documentation required
🔹 Packaging
✔ Tablet / Blister Packaging
✔ Export-Ready Packaging Available
✔ Bulk Supply Supported
🔹 Certifications
✔ WHO-GMP Certified
✔ COA & COPP Available
🌍 Target Export Markets & Cities
🇺🇸 USA: New York, Chicago, Houston
🇬🇧 UK: London, Manchester
🇦🇪 UAE: Dubai, Abu Dhabi
🇸🇬 Singapore: Singapore
🇮🇳 India: Mumbai, Delhi, Bangalore
🇵🇭 Philippines: Manila
🇻🇳 Vietnam: Ho Chi Minh City, Hanoi
🇿🇦 South Africa: Johannesburg, Cape Town
🇳🇬 Nigeria: Lagos, Abuja
🇰🇪 Kenya: Nairobi
🇧🇷 Brazil: São Paulo
🇲🇽 Mexico: Mexico City
🇵🇪 Peru: Lima
📍 Location: Nagpur, Maharashtra, India
📦 Product Catalogue Available
✔ Oncology Medicines
✔ Targeted Cancer Therapies
✔ Specialty Pharmaceutical Products
📞 Instant Support – Call / WhatsApp Now
📲 +91 8007161282
📲 +91 9970011496
📧 Email
✉️ sales@pacificmedicines.com
